Table 2.
Bladder Cancer Stage | Hallmark | Process | TPM Involvement |
---|---|---|---|
Normal | Self-sufficiency in growth signals | Normal expression levels of TPM genes | Tpm 1.6 and Tpm 1.7—formation of stress fibres, cell stability, reduced motility |
Suppression | Insensitivity to growth inhibitory signals | Cell-cycle arrest in G0/G1 if proliferating too much TPM1 + MEG3 causes apoptosis by upregulation of Bcl2 and caspase3 |
TPM1—acts as tumour suppressor |
Initiation | Evasion of programmed cell death | Decreased expression of TPM1 and TPM2 TPM1 is downregulated due to increased micro-RNA 96 (suppression lost) |
Loss of TPM1—EMT Tpm 2.1—responsible for anoikis, maintains cell–cell adhesion |
Non-invasive | Limitless replicative potential | Mutagenic MAPK signalling activated | Tpm3.1—cellular growth, proliferation and motility |
Invasive | Sustained angiogenesis | Invasion into extracellular matrix (ECM) Angiogenesis stimulated by concurrent pathways |
LMW TPMs—formation of lamellipodia, increased cell motility and morphogenesis |
Metastasis | Tissue invasion and death | Breakthrough ECM with distant spread | LMW isoforms of TPM3 and TPM4—Cancer cell survival, focal adhesion, MEK/ERK-mediated proliferation |
Evading immune destruction | Ectopic expression of TPM1 and TPM2 Continued uninhibited anchorage-independent growth |